Latest News
eGenesis Acquires US Cloning Firm ICBiotec
Friday 22 May 2020

Massachusetts, US-based biotechnology company eGenesis has acquired assets and operations of US cloning company ICBiotech, integrating research, cloning and production capabilities to address the shortage of transplantable organs, the company said.

Under the terms of the transaction, eGenesis will acquire ICB's existing facilities, equipment, and land. ICB's research and operations staff will continue as employees of a wholly-owned subsidiary of eGenesis. Financial terms for the transaction were not disclosed.

The acquisition will provide eGenesis with full control of its xeno-organ supply chain.

eGenesis a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs, tissues, and cells to address the global organ shortage.

ICBiotec offers advanced cloning and large animal transgenic production capabilities integral to the xenotransplantation supply chain.
Details
Date Published: 22/05/2020

Options